To gain insights into the patterns of activation of MEG3 gene in the AML pathogenesis, we examined its expression in normal CD34+ bone marrow cells and AML patient samples with different WT1 or TET2 mutation status. This evidence concerns the gene MEG3 and acute myeloid leukemia.